Oxford Cannabinoid Technologies Holdings Plc
Oxford Cannabinoid Technologies Holdings Plc
Your view on OCTHF
Overview
What the company does, where it operates, and who runs it.
About Oxford Cannabinoid Technologies Holdings Plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Clarissa Ann Sowemimo-Coker
- Headquarters
- Maddox House, London, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Clarissa Ann Sowemimo-Coker
- Headquarters
- Maddox House, London, GB
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Infographics
Visual summary of the business at a glance.
Media
Videos and interviews covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks the stock is worth vs. the current price.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Comparables
List of peer companies in the same industry.
Institutional Ownership
Which funds and firms own the stock.
Insider Trading
Recent buying and selling by company executives.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
News
Latest headlines and market coverage.